Orgenesis Inc. (OTCQB: ORGS) is a cell therapy and regenerative medicine company that is focused on developing a cure for Type 1 Diabetes. In pursuit of this goal, the company has developed and patented a novel technology called "cellular trans-differentiation" that turns an insulin-dependent patient's own liver cells into functional insulin producing cells. SNNLive spoke with Vered Caplan, CEO of Orgenesis Inc. at the B. Riley & Co. Investor Conference 2015 in Hollywood, CA.
“Orgenesis is a company that has set a goal to cure diabetes. We’re actually utilizing very innovative regenerative medicine to do that. What we know how to do is take liver cells and turn them into insulin-producing glucose-sensitive cells. So, this is exactly what a diabetic patient would need in order to replace his pancreatic cells,” Ms. Caplan begins.
Vered then goes on to discuss what differentiates the company from others also looking to develop a cure for diabetes. As she describes, “there’s really not a lot of going into curing the disease. The reason is, is that there’s not much technology out there that can actually provide a cure – so, that I would say is the main differentiator – we want to actually provide something to a patient so he doesn’t have to inject insulin, he doesn’t have to worry about his glucose level, he can maintain a normal lifestyle.”
She goes on to tell the story of Professor Ferber and how the company was founded, where the company is located, how the company envisions the therapy to work, and her insight on 2015/2016 for Orgenesis.
For more information about Orgenesis Inc., go to: www.Orgenesis.com
© 2017 Stock News Now
Supported by Superior Web Solutions